IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
|
Int J Clin Exp Med 2012;5(4):306-309
Original Article
Plasma glycosylphosphatidylinositol phospholipase D (GPI-PLD) and abdominal
aortic aneurysm
Markus Lindqvist, Jonas Wallinder, Jörgen Bergström, Anders E Henriksson
Departments of Clinical Chemistry, and Surgery, Sundsvall County Hospital, Sweden. Proteomics Core Facility, University of
Gothenburg, Sweden; Department of Natural Sciences, Mid Sweden University, Sweden
Received June 14, 2012; accepted August 15, 2012; Epub August 20, 2012; Published August 30, 2011
Abstract: Recent reviews state that a circulating biomarker predicting aortic rupture risk would be a powerful tool to stratify patients with
small screen-detected abdominal aortic aneurysm (AAA). In a current proteomic pilot-study elevated levels of the enzyme
Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) was shown in patients with small AAA compared with controls
without aneurysm. In the present study we investigated the impact of plasma GPI-PLD as a biomarker in patients with AAA in relation to
aneurysm size, and rupture. Plasma GPI-PLD was measured in patients with AAA (nonruptured, n=78 and ruptured, n=55) and controls
without aneurysm (n=41) matched by age, sex and smoking habit. The plasma GPI-PLD levels were significantly lower in patients with
ruptured compared nonruptured AAA which we interpreted as a result of hemodilution due to hemorrhage in patients with ruptured AAA.
The plasma GPI-PLD levels were similar in patients with nonruptured AAA compared to the controls without aneurysm. Furthermore,
there was no correlation between plasma GPI-PLD and aneurysm size in the group of patients with nonruptured AAA. In conclusion, the
present study fails to show a connection between GPI-PLD and AAA. However, the definite role of GPI-PLD as a predictive marker
needs to be further clarified in a follow-up cohort study. (IJCEM1206005).
Keywords: Glycosylphosphatidylinositol phospholipase D, biomarker, aortic aneurysm
Address all correspondence to:
Anders Henriksson, MD, PhD
Laboratory Medicine, Sundsvall County Hospital
SE-851 86 Sundsvall, Sweden.
Tel. +46 60 181379
E-mail: anders.henriksson@lvn.se